Robert G. Maki

Professor, Member

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robert G. Maki is a Professor at Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College in the United States. His research areas include early-phase clinical trials, genomic risk stratification in soft tissue sarcomas, and therapeutic targets in chordoma. He has contributed significantly to understanding the mechanisms of action of various treatments in advanced malignancies, including liposarcoma and leiomyosarcoma. His recent publications reflect a focus on innovative approaches to rare cancer clinical research.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Javier Martín-Broto

SPAIN

View details

Piergiuseppe Colombo

Associate Professor

Humanitas University

ITALY

View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES

View details

Mohammed Milhem

Oncology Section Chief

University of Iowa Healthcare

UNITED STATES

View details

Rashmi Chugh

UNITED STATES

View details

Maurizio D'Incalci

Head

IRCCS Humanitas Research Hospital

ITALY

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

David Abramson

Chief, Ophthalmic Oncology

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert G. Maki

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

Early-Phase Trials in Journal of Clinical Oncology

Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma

Assessment of the Mechanisms of Action of Eribulin in Patients with Advanced Liposarcoma Through the Evaluation of Radiological, Functional, and Tissue Responses: A Prospective Monocentric Study (Malibu Study)

The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations

Combining Response and Toxicity Data to Implement Project Optimus

Modeling Extraordinary Response Through Targeting Secondary Alterations in Fusion-Associated Sarcoma

Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.

Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma

Trials and Tribulations in Rare Cancer Clinical Research.

Trials and Tribulations in Rare Cancer Clinical Research

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study.

The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate Toxicity in Randomized Trials of Systemic Cancer Therapy.

Neoadjuvant chemotherapy in patients undergoing neoadjuvant radiation for trunk and extremity soft tissue sarcoma.

Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.

Flashback Foreword: Single-Agent Anti-Programmed Cell Death Protein 1 Therapy for Refractory Solid Tumors.

Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.

Flashback Foreword: Kinase Mutations and Imatinib Response in Patients With Metastatic GI Stromal Tumor.

Flashback Foreword: Kinase Mutations and Imatinib Response in Patients With Metastatic GI Stromal Tumor

Flashback Foreword: Carboplatin Dosage Based on Renal Function.

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Corrigendum to "SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology, vol. 174 (2022), 1-10.

SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology (vol 174, pg 1, 2022)

Collaborators (8)

Javier Martín-Broto

Piergiuseppe Colombo

Bartosz Chmielowski

Mohammed Milhem

Rashmi Chugh

Maurizio D'Incalci

Timothy Yap

David Abramson

Make your next move.